535 related articles for article (PubMed ID: 19201905)
1. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
[TBL] [Abstract][Full Text] [Related]
3. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen.
Itoh T; Ueda Y; Kawashima I; Nukaya I; Fujiwara H; Fuji N; Yamashita T; Yoshimura T; Okugawa K; Iwasaki T; Ideno M; Takesako K; Mitsuhashi M; Orita K; Yamagishi H
Cancer Immunol Immunother; 2002 Apr; 51(2):99-106. PubMed ID: 11904734
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y
Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880
[TBL] [Abstract][Full Text] [Related]
11. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor suppresses autologous tumor killing activity of the peripheral blood lymphocytes in the patients with ovarian carcinoma.
Ohta Y; Hayakawa S; Karasaki-Suzuki M; Sugita K; Komine S; Chishima F; Hatta Y; Horie T; Seo N; Sheikh A; Nemoto N; Yamamoto T
Am J Reprod Immunol; 2004 Jul; 52(1):81-7. PubMed ID: 15214947
[TBL] [Abstract][Full Text] [Related]
13. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy.
Ueda Y; Itoh T; Fuji N; Harada S; Fujiki H; Shimizu K; Shiozaki A; Iwamoto A; Shimizu T; Mazda O; Kimura T; Sonoda Y; Taniwaki M; Yamagishi H
Cancer Immunol Immunother; 2007 Mar; 56(3):381-9. PubMed ID: 16830156
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
Bolonaki I; Kotsakis A; Papadimitraki E; Aggouraki D; Konsolakis G; Vagia A; Christophylakis C; Nikoloudi I; Magganas E; Galanis A; Cordopatis P; Kosmatopoulos K; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Jul; 25(19):2727-34. PubMed ID: 17602077
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
[TBL] [Abstract][Full Text] [Related]
17. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
18. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy.
Yamasaki K; Horiguchi S; Kurosaki M; Kunii N; Nagato K; Hanaoka H; Shimizu N; Ueno N; Yamamoto S; Taniguchi M; Motohashi S; Nakayama T; Okamoto Y
Clin Immunol; 2011 Mar; 138(3):255-65. PubMed ID: 21185787
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
20. Cell transfer regimens in patients with highly advanced surgically unresectable non-small cell lung cancer: significantly improved overall survival in patients with lower levels of serum immunosuppressive acidic protein.
Ebina T; Fujimiya Y
Lung Cancer; 2008 May; 60(2):246-51. PubMed ID: 17980454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
